About BOS complex subunit NOMO3
BOS complex subunit NOMO3 (NOMO3) is a protein
from Homo sapiens identified by UniProt accession
P69849, 1222 residues long.
MolForge cross-references it against 0 known binders and
22 disease associations.
Target properties
| Protein name | BOS complex subunit NOMO3 |
|---|
| UniProt accession | P69849 |
|---|
| Gene | NOMO3 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 1222 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (22)
Diseases linked to this target (Open Targets).
- blood protein measurement · score 0.40
- hemoglobin measurement · score 0.11
- hematocrit · score 0.11
- erythrocyte count · score 0.10
- red blood cell density measurement · score 0.09
- BMI-adjusted hip circumference · score 0.09
- calcium measurement · score 0.09
- mean corpuscular hemoglobin concentration · score 0.09
- creatinine measurement · score 0.08
- sex hormone-binding globulin measurement · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P69849-F1 | alphafold | PREDICTED | 80.35 | — |
Amino-acid sequence (1222 residues)
MLVGQGAGPL GPAVVTAAVV LLLSGVGPAH GSEDIVVGCG GFVKSDVEIN YSLIEIKLYT KHGTLKYQTD CAPNNGYFMI PLYDKGDFIL KIEPPLGWSF EPTTVELHVD GVSDICTKGG DINFVFTGFS VNGKVLSKGQ PLGPAGVQVS LRNTGTEAKI QSTVTQPGGK FAFFKVLPGD YEILATHPTW ALKEASTTVR VTNSNANAAS PLIVAGYNVS GSVRSDGEPM KGVKFLLFSS LVTKEDVLGC NVSPVPGFQP QDESLVYLCY TVSREDGSFS FYSLPSGGYT VIPFYRGERI TFDVAPSRLD FTVEHDSLKI EPVFHVMGFS VTGRVLNGPE GDGVPEAVVT LNNQIKVKTK ADGSFRLENI TTGTYTIHAQ KEHLYFETVT IKIAPNTPQL ADIVATGFSV CGQISIIRFP DTVKQMNKYK VVLSSQDKDK SLVTVETDAH GSFCFKANPG TYKVQVMVPE AETRAGLTLK PQTFPLTVTD RPVMDVAFVQ FLASVSGKVS CLDTCGDLLV TLQSLSRQGE KRSLQLSGKV NAMTFTFDNV LPGKYKISIM HEDWCWKNKS LEVEVLEDDV SAVEFRQTGY MLRCSLSHAI TLEFYQDGNG RENVGIYNLS KGVNRFCLSK PGVYKVTPRS CHRFEQAFYT YDTSSPSILT LTAIRHHVLG TITTDKMMDV TVTIKSSIDS EPALVLGPLK SVQELRREQQ LAEIEARRQE REKNGNEEGE ERMTKPPVQE MVDELQGPFS YDFSYWARSG EKITVTPSSK ELLFYPPSME AVVSGESCPG KLIEIHGKAG LFLEGQIHPE LEGVEIVISE KGASSPLITV FTDDKGAYSV GPLHSDLEYT VTSQKEGYVL TAVEGTIGDF KAYALAGVSF EIKAEDDQPL PGVLLSLSGG LFRSNLLTQD NGILTFSNLS PGQYYFKPMM KEFRFEPSSQ MIEVQEGQNL KITITGYRTA YSCYGTVSSL NGEPEQGVAM EAVGQNDCSI YGEDTVTDEE GKFRLRGLLP GCVYHVQLKA EGNDHIERAL PHHRVIEVGN NDIDDVNIIV FRQINQFDLS GNVITSSEYL PTLWVKLYKS ENLDNPIQTV SLGQSLFFHF PPLLRDGENY VVLLDSTLPR SQYDYILPQV SFTAVGYHKH ITLIFNPTRK LPEQDIAQGS YIALPLTLLV LLAGYNHDKL IPLLLQLTSR LQGVGALGQA ASDNSGPEDA KRQAKKQKTR RT
Explore BOS complex subunit NOMO3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets